Continuous chromatography is not fully replacing batch processing in biotech manufacturing, but it is rapidly gaining ground as a preferred approach for many downstream processing workflows. The shift is driven by mounting pressure on biopharmaceutical manufacturers to improve yield, reduce buffer consumption, and lower the cost of goods at scale. This article unpacks the key questions surrounding continuous chromatography, from how it works to where regulators stand today.
What are the main limitations of batch chromatography in biotech?
Batch chromatography, the long-established method for purifying biologics, suffers from inherent inefficiencies that become increasingly costly at manufacturing scale. In a batch process, the column is loaded to a fraction of its theoretical capacity, then washed, eluted, and regenerated before the next cycle begins. This sequential, stop-start workflow leaves significant productivity on the table.
The core limitations include:
- Low resin utilization: To prevent product from breaking through the column, loading is stopped well before the resin reaches saturation, meaning expensive chromatography media is routinely underused.
- High buffer consumption: Each cycle requires substantial volumes of equilibration, wash, and regeneration buffers, adding to operational costs and waste streams.
- Large equipment footprint: Achieving high throughput in batch mode requires large columns or multiple parallel units, increasing capital expenditure and facility space.
- Process discontinuity: Batch chromatography is inherently disconnected from upstream bioreactor output, creating hold steps, intermediate storage needs, and potential product quality risks.
- Limited scalability: Scaling up a batch chromatography process often introduces mass transfer and flow distribution challenges that are difficult to predict from small-scale development runs.
These limitations are particularly acute in the production of monoclonal antibodies, recombinant proteins, and other high-value biologics, where downstream processing can account for a substantial portion of total manufacturing cost.
How does continuous chromatography work in a bioprocessing context?
Continuous chromatography in bioprocessing uses multiple columns operated in a staggered, overlapping sequence so that loading, washing, elution, and regeneration steps occur simultaneously across different columns. Rather than running one column through its full cycle before beginning the next, the system cycles columns in and out of each phase continuously, eliminating the idle time inherent in batch operation.
The most widely discussed format is multicolumn countercurrent solvent gradient purification, often referred to by its principle: product that breaks through one column during loading is captured by the next column in line, ensuring that resin capacity is used to near saturation before any column moves to the wash and elution phase. This countercurrent loading strategy is what fundamentally distinguishes continuous chromatography from simply running multiple batch columns in parallel.
In a fully integrated continuous bioprocessing line, the chromatography step connects directly to the upstream bioreactor harvest, with inline conditioning and real-time process monitoring enabling uninterrupted product flow. Automated valve switching, precise pump control, and inline analytical tools are essential to maintaining consistent performance across the interconnected column sequence.
What are the proven advantages of continuous chromatography over batch?
The proven advantages of continuous chromatography over batch processing center on higher resin productivity, lower buffer use, reduced equipment size, and better integration with continuous upstream processes. These gains are well documented across capture steps, particularly protein A affinity chromatography for monoclonal antibodies.
Key advantages that industry experience consistently supports include:
- Significantly higher resin utilization: By loading columns to near saturation through countercurrent capture, continuous systems extract far more product per liter of resin per day than batch equivalents.
- Reduced buffer consumption: Overlapping column cycles and optimized gradient profiles cut buffer volumes substantially, lowering raw material costs and environmental impact.
- Smaller equipment footprint: Higher productivity per column means manufacturers can achieve the same output with smaller columns, reducing capital investment and facility requirements.
- Improved process consistency: Steady-state continuous operation can reduce batch-to-batch variability because process conditions are maintained within tighter ranges over time.
- Easier integration with continuous upstream: Continuous chromatography eliminates the need for large intermediate hold tanks, reducing product exposure time and the associated stability risks.
Which biotech applications are best suited for continuous chromatography?
Continuous chromatography is best suited for high-volume, high-value biologic production where resin cost, buffer consumption, and facility footprint are significant economic drivers. Monoclonal antibody manufacturing is the most established application, but the approach is increasingly relevant across a broader range of biologics.
Applications where continuous chromatography delivers the strongest fit include:
- Monoclonal antibody capture and polishing in biopharmaceutical manufacturing
- Recombinant protein purification in both research and commercial production settings
- Viral vector purification for gene therapy research, where yield from expensive starting material is critical
- Plasma protein fractionation, where large volumes and tight purity requirements favor continuous operation
- Biosimilar production, where cost-of-goods pressure makes process efficiency a competitive advantage
In the Benelux region, research institutions and biopharmaceutical development organizations are actively exploring continuous downstream processing as part of broader process intensification programs, making this a topic of growing practical relevance for labs at various stages of development and scale.
What are the biggest implementation challenges for continuous chromatography?
The biggest implementation challenges for continuous chromatography are process complexity, the need for robust automation and inline analytics, and the significant investment required in method development and validation. Transitioning from batch to continuous is not a drop-in change; it requires a rethinking of the entire downstream workflow.
Specific challenges that organizations consistently encounter include the difficulty of maintaining steady-state operation across multiple interconnected columns, each of which must perform consistently over many cycles. Resin lifetime and cleaning validation become more complex because columns accumulate significantly more cycles in a continuous format than in batch operation.
Inline process analytical technology is essential for continuous chromatography to function reliably. UV absorbance, conductivity, and pH sensors must provide real-time data that automated control systems can act on without human intervention. Building and validating this level of automation requires expertise that many labs are still developing.
Process development timelines can also be longer for continuous systems, since optimizing the interconnected column sequence involves more variables than a single-column batch method. Organizations new to continuous bioprocessing often benefit from phased implementation, starting with a single continuous capture step before integrating further downstream unit operations.
Is continuous chromatography approved and accepted by regulators?
Continuous chromatography is accepted by major regulatory agencies, including the FDA and EMA, as a valid approach for biopharmaceutical manufacturing, provided that the process is thoroughly characterized, controlled, and validated. Regulatory frameworks such as ICH Q8, Q9, and Q10 support the adoption of continuous and intensified manufacturing approaches when they are underpinned by a robust quality-by-design strategy.
Regulators do not require manufacturers to use batch processing. What they require is a clear demonstration that the process is understood, controlled within defined parameters, and consistently produces product of the required quality. Continuous chromatography processes must be validated with the same rigor as batch processes, including demonstration of column lifetime, cleaning effectiveness, and the impact of process deviations.
General industry guidance emphasizes that process analytical technology and real-time release testing are important enablers of regulatory acceptance for continuous processes. Manufacturers pursuing continuous chromatography should engage with regulators early in development and document process understanding thoroughly to support approval submissions. The regulatory landscape in 2026 continues to evolve in ways that are broadly supportive of continuous and intensified manufacturing across the biopharmaceutical sector.
How ChemSPX supports continuous and preparative chromatography in the Benelux
ChemSPX helps research and development teams in the Benelux navigate the transition toward more efficient chromatography workflows. Whether you are evaluating preparative chromatography options for the first time or looking to intensify an existing downstream process, ChemSPX’s team of Sales Engineers and Product Specialists provides hands-on support at every stage.
- Expert advice on chromatography system selection and configuration for your specific application
- Application-level support for method development and system optimization
- Installation, qualification (IQ/OQ), and calibration services in line with GMP and GLP standards
- Ongoing service and maintenance to maximize instrument uptime and lifetime
- Local support from specialists based in the Netherlands and Belgium
If you are exploring continuous chromatography or want to improve your current preparative purification workflows, contact ChemSPX to speak with a specialist who understands your application and your region.
Foire aux questions
How do I know if my current batch chromatography process is a good candidate for conversion to a continuous format?
The strongest candidates for conversion are processes where resin cost is a significant budget line, where upstream titers are high enough to create bottlenecks at the capture step, or where facility footprint and buffer consumption are limiting scale-up. A practical first step is to benchmark your current resin utilization and buffer volumes per gram of product; if resin is being loaded to less than 60–70% of its dynamic binding capacity, continuous countercurrent loading is likely to deliver meaningful gains. Consulting with a chromatography specialist who can model your specific titer, column size, and cycle parameters will give you a clearer picture of the expected return before committing to a full process development effort.
What is the minimum number of columns needed to run a true continuous chromatography process?
Most continuous chromatography configurations use a minimum of two columns to enable countercurrent loading, where breakthrough from the first column is captured by the second, but three or four columns are more common in practice because they allow loading, washing, elution, and regeneration to occur simultaneously without creating idle time. The optimal number of columns depends on the relative duration of each process step: if your elution and regeneration cycle is long relative to loading, more columns are needed to maintain true continuity. System vendors and process development tools can help model the ideal column number for your specific step times and productivity targets.
What happens to product quality if one column in a continuous system underperforms or fails mid-run?
This is one of the most important risk management questions in continuous chromatography, and robust process design addresses it through real-time inline monitoring and automated divert logic. If a UV, conductivity, or pH sensor detects an out-of-specification signal on any column, a well-designed control system can divert that column’s output to waste and flag the deviation without stopping the entire process. That said, defining these divert criteria, validating the control response, and understanding the impact on overall yield requires thorough process characterization during development — this is precisely where investing in process analytical technology and automation expertise pays off.
How does resin lifetime and cleaning validation work differently in a continuous chromatography process compared to batch?
In continuous operation, columns accumulate cycles far more rapidly than in batch, which means resin lifetime studies must be designed to cover a much higher number of cycles — often several hundred — while demonstrating consistent performance and cleaning effectiveness throughout. Cleaning validation is more complex because the interconnected column sequence means cleaning agents and contact times must be optimized without disrupting the overall process schedule. Regulatory agencies expect manufacturers to define and justify the maximum number of cycles a resin can undergo, supported by data on product quality attributes, leachables, and microbial control at the end of the validated lifetime.
Can continuous chromatography be implemented incrementally, or does it require a full process overhaul from the start?
Incremental implementation is not only possible but is widely recommended as the most practical path for organizations new to continuous downstream processing. The most common starting point is replacing a single batch capture step — typically protein A affinity chromatography — with a continuous multicolumn format, while keeping the rest of the downstream workflow unchanged. Once that step is running reliably and the team has built confidence in the automation and monitoring requirements, additional unit operations can be integrated progressively. This phased approach reduces technical risk, limits the scope of initial validation work, and allows the organization to build internal expertise before committing to a fully integrated continuous process.
What analytical and automation infrastructure do I need in place before implementing continuous chromatography?
At a minimum, you need reliable inline sensors for UV absorbance, conductivity, and pH on each column outlet, along with a control system capable of executing automated valve switching based on real-time sensor data without manual intervention. A data historian or process monitoring platform that logs all sensor signals and valve events is essential for both process control and regulatory documentation. Many teams also integrate inline or at-line protein concentration measurement to enable real-time yield tracking; if your current infrastructure does not support this level of automation, that gap should be addressed before or in parallel with continuous chromatography implementation, rather than after.
Are there specific continuous chromatography platforms or system vendors that are commonly used in Benelux bioprocessing environments?
Several established chromatography system vendors offer dedicated continuous or multicolumn chromatography platforms that are used across European bioprocessing environments, including systems designed specifically for countercurrent loading configurations at both lab and manufacturing scale. The right platform depends on your application, scale, required level of automation, and whether the system needs to integrate with existing upstream equipment. Working with a local specialist — such as ChemSPX’s team in the Netherlands and Belgium — gives you access to application-specific guidance on system selection, configuration, and qualification that accounts for both your technical requirements and the regulatory standards applicable in your region.
Articles connexes
- How does moisture content affect pharmaceutical powder flow?
- What causes loss of yield during chromatographic purification?
- What is purification used for in a laboratory?
- How does reverse phase chromatography differ from normal phase?
- How do you troubleshoot poor resolution in chromatography?
Ce contenu a été généré à l'aide de l'IA et peut contenir des erreurs.